Scientists probe Mepolizumab's effect on nasal cell health

NCT ID NCT05895929

Completed Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early lab study from Johns Hopkins University examines how mepolizumab (Nucala) affects the health and function of nasal cells from people with chronic sinusitis and nasal polyps. Researchers will measure changes in inflammation markers and cell barrier integrity. Only 8 participants are enrolled, and the work is done on cells in a dish, not in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mepolizumab (Nucala)
What this could lead to: If it works, this could point toward a better understanding of how mepolizumab helps maintain nasal cell health in chronic sinusitis with nasal polyps.
What could go wrong: This is a very early lab study with only 8 participants, so results may not apply to real-world treatment. It tests cells in a dish, not in people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic rhinosinusitis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC RHINOSINUSITIS (DIAGNOSIS) CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Contacts and locations

Locations

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, 21117, United States
Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.